Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| dendritic cell | 14 studies | 33% ± 15% | |
| plasmacytoid dendritic cell | 10 studies | 28% ± 10% | |
| conventional dendritic cell | 9 studies | 39% ± 17% | |
| GABAergic neuron | 4 studies | 34% ± 10% | |
| hematopoietic stem cell | 3 studies | 36% ± 14% |
Insufficient scRNA-seq data for expression of FLT3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| pancreas | 100% | 316.67 | 327 / 328 | 60% | 2.28 | 107 / 178 |
| breast | 55% | 47.93 | 251 / 459 | 68% | 6.53 | 762 / 1118 |
| lung | 85% | 184.70 | 493 / 578 | 31% | 0.60 | 360 / 1155 |
| spleen | 99% | 632.44 | 239 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 92% | 661.63 | 857 / 929 | 0% | 0 | 0 / 0 |
| intestine | 75% | 134.05 | 724 / 966 | 9% | 0.33 | 49 / 527 |
| kidney | 39% | 69.31 | 35 / 89 | 44% | 1.46 | 393 / 901 |
| brain | 64% | 499.12 | 1679 / 2642 | 16% | 0.33 | 116 / 705 |
| skin | 53% | 51.68 | 959 / 1809 | 21% | 0.55 | 97 / 472 |
| bladder | 57% | 54.10 | 12 / 21 | 11% | 0.19 | 57 / 504 |
| stomach | 47% | 32.53 | 168 / 359 | 16% | 0.30 | 47 / 286 |
| adipose | 62% | 72.94 | 751 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 62% | 2.31 | 18 / 29 |
| tonsil | 0% | 0 | 0 / 0 | 60% | 1.27 | 27 / 45 |
| prostate | 42% | 43.33 | 103 / 245 | 17% | 0.29 | 87 / 502 |
| esophagus | 41% | 33.83 | 593 / 1445 | 12% | 0.28 | 22 / 183 |
| thymus | 29% | 32.72 | 190 / 653 | 23% | 0.72 | 141 / 605 |
| uterus | 39% | 27.51 | 67 / 170 | 13% | 0.28 | 58 / 459 |
| blood vessel | 42% | 40.82 | 555 / 1335 | 0% | 0 | 0 / 0 |
| adrenal gland | 34% | 24.09 | 88 / 258 | 2% | 0.03 | 4 / 230 |
| liver | 12% | 7.72 | 28 / 226 | 8% | 0.22 | 32 / 406 |
| ovary | 8% | 7.00 | 15 / 180 | 5% | 0.11 | 23 / 430 |
| heart | 13% | 7.75 | 108 / 861 | 0% | 0 | 0 / 0 |
| muscle | 2% | 0.79 | 13 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0042531 | Biological process | positive regulation of tyrosine phosphorylation of STAT protein |
| GO_0019221 | Biological process | cytokine-mediated signaling pathway |
| GO_0001776 | Biological process | leukocyte homeostasis |
| GO_0030097 | Biological process | hemopoiesis |
| GO_0007169 | Biological process | cell surface receptor protein tyrosine kinase signaling pathway |
| GO_0007275 | Biological process | multicellular organism development |
| GO_0031100 | Biological process | animal organ regeneration |
| GO_0043410 | Biological process | positive regulation of MAPK cascade |
| GO_0097028 | Biological process | dendritic cell differentiation |
| GO_0046651 | Biological process | lymphocyte proliferation |
| GO_0038084 | Biological process | vascular endothelial growth factor signaling pathway |
| GO_0043406 | Biological process | positive regulation of MAP kinase activity |
| GO_0033674 | Biological process | positive regulation of kinase activity |
| GO_0018108 | Biological process | peptidyl-tyrosine phosphorylation |
| GO_0071345 | Biological process | cellular response to cytokine stimulus |
| GO_0042981 | Biological process | regulation of apoptotic process |
| GO_0002328 | Biological process | pro-B cell differentiation |
| GO_0010243 | Biological process | response to organonitrogen compound |
| GO_0035726 | Biological process | common myeloid progenitor cell proliferation |
| GO_0051897 | Biological process | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
| GO_0008284 | Biological process | positive regulation of cell population proliferation |
| GO_0071385 | Biological process | cellular response to glucocorticoid stimulus |
| GO_0002318 | Biological process | myeloid progenitor cell differentiation |
| GO_0046777 | Biological process | protein autophosphorylation |
| GO_0030183 | Biological process | B cell differentiation |
| GO_0043235 | Cellular component | receptor complex |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0005788 | Cellular component | endoplasmic reticulum lumen |
| GO_0005783 | Cellular component | endoplasmic reticulum |
| GO_0010008 | Cellular component | endosome membrane |
| GO_0141038 | Molecular function | phosphatidylinositol 3-kinase activator activity |
| GO_0005021 | Molecular function | vascular endothelial growth factor receptor activity |
| GO_0035259 | Molecular function | nuclear glucocorticoid receptor binding |
| GO_0044877 | Molecular function | protein-containing complex binding |
| GO_0004713 | Molecular function | protein tyrosine kinase activity |
| GO_0004714 | Molecular function | transmembrane receptor protein tyrosine kinase activity |
| GO_0004896 | Molecular function | cytokine receptor activity |
| GO_0019838 | Molecular function | growth factor binding |
| GO_0005524 | Molecular function | ATP binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | FLT3 |
| Protein name | FLT3 Fms-like tyrosine kinase 3 receptor protein-tyrosine kinase (EC 2.7.10.1) Receptor-type tyrosine-protein kinase FLT3 (EC 2.7.10.1) (FL cytokine receptor) (Fetal liver kinase-2) (FLK-2) (Fms-like tyrosine kinase 3) (FLT-3) (Stem cell tyrosine kinase 1) (STK-1) (CD antigen CD135) |
| Synonyms | CD135 STK1 FLK2 |
| Description | FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways. . |
| Accessions | A0A4P8K7E7 E7ER61 P36888 A0A6G6D0I3 A0A6G6D048 A0A6G6D079 A0A6G6D045 ENST00000241453.12 [P36888-1] ENST00000380987.2 |
